<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295593</url>
  </required_header>
  <id_info>
    <org_study_id>VPA-CdA</org_study_id>
    <nct_id>NCT01295593</nct_id>
  </id_info>
  <brief_title>Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)</brief_title>
  <official_title>Phase I-II Study of Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia (CLL) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale New chemotherapeutic agents are needed in relapsing B-Cell Chronic Lymphocytic&#xD;
      Leukemia (B-CLL) to overcome resistance of CLL cells. Valproic acid (VPA) is an inhibitor of&#xD;
      histone deacetylase (HDAC) used as an anticonvulsant and mood-stabilizing drug for decades.&#xD;
      VPA mediates apoptosis in CLL cells through caspase activation. VPA shows toxicity toward CLL&#xD;
      cells displaying alterations in the p53 pathway. The combination of VPA with fludarabine or&#xD;
      2-Chlorodeoxyadenosine (CdA, Cladribine) results in synergistic loss of B-CLL cell viability,&#xD;
      and significant increase in apoptosis. The highest index of synergism is observed between VPA&#xD;
      and CdA, a purine nucleoside analog active in B-CLL.&#xD;
&#xD;
      Study design Overall, the study will be proposed to previously treated patients with advanced&#xD;
      B-CLL, who are not eligible for aggressive approaches, and who exhibit progressive disease. A&#xD;
      total of 33 patients will be included. Estimated enrolment time is 2 years.&#xD;
&#xD;
        -  First part: It is planned to start therapy with single VPA during 2 months, targeting&#xD;
           plasma levels that have been reported to be active in vitro toward CLL cells (but that&#xD;
           do not exceed therapeutic levels in seizure prevention), and in parallel, to verify&#xD;
           whether cellular targets of VPA have been actually inhibited in leukemic B-lymphocytes.&#xD;
&#xD;
        -  Second part: After the VPA preloading period (2 months), patients will be evaluated to&#xD;
           receive CdA. CdA will be given at 5.6 mg/m²/day intravenously during 3 days, a&#xD;
           reduced-dose schedule which is less toxic - at no obvious cost of loss of efficacy - as&#xD;
           compared to the standard dosage of 5 days. CdA was chosen because it displays the&#xD;
           highest level of in vitro synergism with VPA. Four monthly courses of CdA will be given.&#xD;
           Patients will then be evaluated. VPA will be stopped at the time of response evaluation&#xD;
           (scheduled 28 days after the last course of CdA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the tolerability of VPA in combination with low dose CdA in patients with advanced B-CLL</measure>
    <time_frame>6 months on average</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>minimal dose of VPA able to achieve adequate plasma levels of VPA and effective inhibition of VPA cellular targets, therapeutic response and survival , VPA pharmacokinetics</measure>
    <time_frame>6 months on average</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>valproic acid combined with CdA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>valproic acid, oral daily intake, combined with 2-chlorodeoxyadenosine administered intravenously for 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valproic acid and 2-chlorodeoxyadenosine</intervention_name>
    <description>VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles</description>
    <arm_group_label>valproic acid combined with CdA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  B-cell Chronic Lymphocytic Leukemia (CLL)&#xD;
&#xD;
          -  Patients must have intermediate or high-risk categories of the modified 3-stage Rai&#xD;
             and Binet staging&#xD;
&#xD;
          -  Patient MUST have progressive or symptomatic disease as defined by any of the&#xD;
             following conditions:&#xD;
&#xD;
               -  Progressive lymphocytosis with a lymphocyte count increased &gt; 50% over the last 2&#xD;
                  months period or an anticipation of the doubling time in less than 6 months&#xD;
&#xD;
               -  Progressive or symptomatic splenomegaly or hepatomegaly&#xD;
&#xD;
               -  Progressive or symptomatic lymphadenopathy&#xD;
&#xD;
               -  Evidence of progressive marrow failure as manifested by development or worsening&#xD;
                  of anemia and/or thrombocytopenia&#xD;
&#xD;
               -  Presence of any B-symptoms: weight loss ≥ 10% within the previous 6 months, fever&#xD;
                  &gt; 38.0°C for ≥ 2 weeks without evidence of infection, or night sweats without&#xD;
                  evidence of infection&#xD;
&#xD;
          -  Patient must have received one or more prior therapies for Chronic Lymphocytic&#xD;
             Leukemia. Patients may have received any of the following prior treatment regimens:&#xD;
             fludarabine-containing combinations, alemtuzumab single agent or combination,&#xD;
             rituximab combinations, chlorambucil, cyclophosphamide +/- prednisone, or other forms&#xD;
             of immunotherapy…&#xD;
&#xD;
          -  Patients must have adequate organ function:&#xD;
&#xD;
               -  Neutrophils &gt; 500/mm³&#xD;
&#xD;
               -  Platelets &gt; 50.000/mm³&#xD;
&#xD;
               -  Creatinine clearance (measured or calculated) &gt; 40 ml/min&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Patient's ECOG performance status must be 0-2&#xD;
&#xD;
          -  Patient's written informed consent&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients having received Valproic Acid (VPA) within 3 months&#xD;
&#xD;
          -  Previous, suspected or known hypersensitivity to VPA, or any of its derivatives&#xD;
&#xD;
          -  Liver porphyria&#xD;
&#xD;
          -  Epilepsy due to mitochondrial diseases&#xD;
&#xD;
          -  Ongoing treatment with VPA-interacting drugs&#xD;
&#xD;
          -  Cumulative Illness rating Scale (CIRS) &gt; 6&#xD;
&#xD;
          -  Prior allogenic or autologous bone marrow transplantation less than 12 months&#xD;
&#xD;
          -  Patient having received any anticancer agents (chemotherapy, immunotherapy or targeted&#xD;
             agents) within 4 weeks&#xD;
&#xD;
          -  Central Nervous System involvement&#xD;
&#xD;
          -  Concomitant disease requiring prolonged use of corticosteroids (&gt; 1 month)&#xD;
&#xD;
          -  Transformation into an aggressive B-cell malignancy (e.g. diffuse large cell lymphoma,&#xD;
             Hodgkin lymphoma)&#xD;
&#xD;
          -  Creatinine clearance &lt; 40 ml/min calculated according to the formula of Cockcroft and&#xD;
             Gault. Patients with a calculated creatinine clearance below 40 ml/min may be eligible&#xD;
             if (1) a measured creatinine clearance (based on 24 hours urine collection or other&#xD;
             reliable method) is &gt; 40 ml/min, or (2) a new calculation conducted after adequate&#xD;
             hydration is &gt; 40 ml/min.&#xD;
&#xD;
          -  Any coexisting medical or psychological condition that would preclude participation to&#xD;
             the required study procedures&#xD;
&#xD;
          -  Patient with mental deficiency preventing proper understanding of the requirements of&#xD;
             treatment&#xD;
&#xD;
          -  Pregnancy, lactating woman, females of childbearing potential or male patient who are&#xD;
             unwilling to use adequate contraception&#xD;
&#xD;
          -  Clinically significant auto-immune cytopenia, Coombs-positive hemolytic anemia as&#xD;
             judged by the treating physician&#xD;
&#xD;
          -  Patients with a history of another malignancy in complete remission less than 2 years,&#xD;
             except basal cell skin cancer, stage 0 (in situ) cervical carcinoma or tumor treated&#xD;
             curatively by surgery&#xD;
&#xD;
          -  Any severe co-morbidities such as New York Heart Association Class III or IV heart&#xD;
             failure, myocardial infarction within 6 months, unstable angina, ventricular&#xD;
             tachyarrhythmias requiring ongoing treatment, or severe uncontrolled myocardiopathy,&#xD;
             uncontrolled hypertension, severe chronic obstructive pulmonary disease with hypoxemia&#xD;
             or uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Active bacterial, viral or fungal infection&#xD;
&#xD;
          -  Seropositivity for: Human Immunodeficiency Virus, hepatitis C or hepatitis B (unless&#xD;
             clearly due to vaccination)&#xD;
&#xD;
          -  Liver insufficiency&#xD;
&#xD;
          -  Total bilirubin &gt; 2 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Prior history of severe hepatic or pancreatic disorder&#xD;
&#xD;
          -  Alkaline phosphatases and aminotransferases (AST, ALT) &gt; 2 x ULN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Van Den Neste, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Van Den Neste, MD, PhD</last_name>
    <phone>+32 27 64 18 00</phone>
    <email>eric.vandenneste@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabrina Costantini</last_name>
    <phone>+32 27 64 18 09</phone>
    <email>sabrina.costantini@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Sud Luxembourg</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Pierre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Bron, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ULB Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Kentos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Van Den Neste, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleori - Site notre Dame</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc André, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Notre-Dame de Grâce</name>
      <address>
        <city>Gosselies</city>
        <zip>6041</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Maerevoet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jolimont</name>
      <address>
        <city>Haine-St-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Delrieu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU ULg</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard De Prijck, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Pierre</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Connerotte, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heilig-Hartziekenhuis</name>
      <address>
        <city>Roeselaere</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilde Demuynck, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques de Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Chatelain, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL previously treated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

